KaloBios Investors Take $1.5M Deal But Still Target Shkreli
KaloBios Pharmaceuticals and two executives have agreed to shell out $1.5 million to settle part of a putative securities class action sparked by pharmaceutical executive Martin Shkreli's one-month tenure as KaloBios...To view the full article, register now.
Already a subscriber? Click here to view full article